Macquarie Group LTD Biocryst Pharmaceuticals Inc Transaction History

Macquarie Group LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$10.79 - $14.81 $14,048 - $19,282	-1,302 Reduced 20.6%	5,019 $80,000
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $22,935 - $39,203	-1,984 Reduced 23.89%	6,321 $103,000
Q4 2021 Feb 11, 2022	BUY	$11.18 - $15.46 $20,157 - $27,874	1,803 Added 27.73%	8,305 $115,000
Q3 2021 Nov 12, 2021	SELL	$14.21 - $17.65 $29,883 - $37,117	-2,103 Reduced 24.44%	6,502 $93,000
Q2 2021 Aug 13, 2021	BUY	$9.5 - $17.24 $2,403 - $4,361	253 Added 3.03%	8,605 $136,000
Q1 2021 May 14, 2021	SELL	$7.37 - $13.61 $11,644 - $21,503	-1,580 Reduced 15.91%	8,352 $85,000
Q3 2020 Nov 13, 2020	BUY	$3.43 - $5.53 $10,976 - $17,696	3,200 Added 47.53%	9,932 $34,000
Q2 2020 Aug 11, 2020	BUY	$1.9 - $5.61 $12,790 - $37,766	6,732 New	6,732 $32,000
Q1 2018 May 11, 2018	SELL	$4.35 - $5.82 $7,829 - $10,476	-1,800 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$4.16 - $5.33 $7,488 - $9,594	1,800	1,800 $9,000

257

173M

397K

444K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.57B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.